NewsRx

Search our medical news database

Wilson Disease News and Articles

Return to Library

NewsRx Bundle

A quick and inexpensive way to view the most recent articles for a one-time project.

Custom Reports on Wilson Disease

Tired of prepackaged reports that just don't meet your needs? Target your needs!

What is Wilson disease?

Wilson disease is an inherited disorder in which excessive amounts of copper accumulate in the body, particularly in the liver, brain, and eyes. Symptoms of Wilson disease usually appear between the ages of 6 and 40, but most often begin during the teenage years. In children, liver disease is the most common feature. Signs and symptoms of liver disease include yellowing of the skin or the whites of the eye (jaundice), fatigue, loss of appetite, and abdominal swelling. Psychiatric and nervous system problems are common in young adults with Wilson disease. Signs and symptoms can include clumsiness, trembling, difficulty walking, speech problems, deteriorating school work, depression, anxiety, and mood swings. In many individuals with Wilson disease, copper deposits form a green-to-brownish ring, called the Kayser-Fleischer ring, around the cornea (the front surface of the eye).

How common is Wilson disease?

Wilson disease is a rare disorder that affects approximately 1 in 30,000 individuals.

What genes are related to Wilson disease?

Mutations in the ATP7B gene cause Wilson disease.

The ATP7B gene makes a protein important for copper transport and the elimination of excess copper from the body. The mutated gene prevents the transport protein from functioning properly, allowing copper to accumulate in the liver, brain, and other tissues.

How do people inherit Wilson disease?

This condition is inherited in an autosomal recessive pattern, which means two copies of the gene in each cell are altered. Most often, the parents of an individual with an autosomal recessive disorder each carry one copy of the altered gene but do not show signs and symptoms of the disorder.

Source: National Institutes of Health

Recent Wilson Disease News and Articles


Data from University of Cairo Provide New Insights into Bacterial Infections

2012 OCT 31 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- A new study on Bacterial Infections is now available. According to news reporting originating from Cairo, Egypt, by NewsRx correspondents, research stated, "Treatment of the causes of many chronic liver diseases (CLDs) may not be possible. In this case, complications must be anticipated, prevented or at least controlled by the best available therapeutic modalities."

Our news editors obtained a quote from the research from the University of Cairo, "There are three main goals for the management of portal hypertension: (i) prevention of the first episode of variceal bleeding largely by non-selective ß-adrenoceptor antagonists, which is not generally recommended in children; (ii) control of bleeding by using a stepwise approach from the least to most invasive strategies; (iii) and prevention of re-bleeding using bypass operations, with particular enthusiasm for the use of meso-Rex bypass in the pediatric population. Hepatic encephalopathy management also consists of three main aspects: (i) ruling out other causes of encephalopathy; (ii) identifying and treating precipitating factors; and (iii) starting empiric treatment with drugs such as lactulose, rifaximin, sodium benzoate, and flumazenil. Treatment of mild ascites and peripheral edema should begin with the restriction of sodium and water, followed by careful diuresis, then large-volume paracentesis associated with colloid volume expansion in severe cases. Empiric broad spectrum antimicrobial therapy should be used for the treatment of spontaneous bacterial peritonitis, bacterial and fungal sepsis, and cholangitis, after taking appropriate cultures, with appropriate changes in therapy after sensitivity testing. Empirical therapies continue to be the standard practice for pruritus; these consist of bile acid binding agents, phenobarbital (phenobarbitone), ursodeoxycholic acid, antihistamines, rifampin (rifampicin), and carbamazepine. Partial external biliary diversion can be used in refractory cases. Once hepatorenal syndrome is suspected, treatment should be initiated early in order to prevent the progression of renal failure; approaches consist of general supportive measures, management of concomitant complications, screening for sepsis, treatment with antibiotics, use of vasopressin analogs (terlipressin), and renal replacement therapy if needed. Hepatopulmonary syndrome and portopulmonary hypertension are best managed by liver transplantation. Provision of an adequate caloric supply, nutrition, and vitamin/mineral supplements for the management of growth failure, required vaccinations, and special care for ensuring psychologic well-being should be ensured. Anticoagulation might be attempted in acute portal vein thrombosis. Some CLDs, such as extrahepatic biliary atresia (EHBA), Crigler-Najjar syndrome, and Indian childhood cirrhosis, require special considerations. For EHBA, Kasai hepatoportoenterostomy is the current standard surgical approach in combination with nutritional therapy and supplemental fat and water soluble vitamins, minerals, and trace elements. In type 1 Crigler-Najjar syndrome, extensive phototherapy is the mainstay of treatment, in association with adjuvant therapy to bind photobilirubin such as calcium phosphate, cholestyramine, or agar, until liver transplantation can be carried out. Treating Indian childhood cirrhosis with penicillamine early in the course of the disease and at doses similar to those used to treat Wilson disease decreases the mortality rate by half. New hopes for the future include extracorporeal liver support devices (the molecular adsorbent recirculating system [MARS®] and Prometheus®), hepatocyte transplantation, liver-directed gene therapy, genetically engineered enzymes, and therapeutic modalities targeting fibrogenesis."

According to the news editors, the research concluded: "Hepapoietin, a naturally occurring cytokine that promotes hepatocyte growth, is under extensive research."

For more information on this research see: Medical management of chronic liver diseases (CLD) in children (part II): focus on the complications of CLD, and CLD that require special considerations. Paediatric Drugs, 2011;13(6):371-83. Paediatric Drugs can be contacted at: Adis International LTD, 41 Centorian Dr, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.

The news editors report that additional information may be obtained by contacting M.H. El-Shabrawi, Faculty of Medicine, Cairo University, Mohandesseen, Cairo, Egypt.

Publisher contact information for the journal Paediatric Drugs is: Adis International LTD, 41 Centorian Dr, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.

Keywords for this news article include: Cairo, Egypt, Africa, Genetics, Hepatology, Pediatrics, Bacterial Infections, Chronic Liver Diseases, Digestive System Diseases.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC

NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook